Middle East respiratory syndrome

The Lancet

Volumn 395, Issue 10229, 2020, Pages 1063-1077

  Memish, Ziad A ^a,b,c   Perlman, Stanley ^d   Van Kerkhove, Maria D ^e   Zumla, Alimuddin ^f,g  

^a ALFAISAL UNIVERSITY   (Saudi Arabia)

^b Riyadh Regional Laboratory   (Saudi Arabia)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID DERIVATIVE; DNA VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; SUBUNIT VACCINE; VIRUS VECTOR; VITRONECTIN;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; CLINICAL OUTCOME; COMORBIDITY; CONVALESCENT PLASMA; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DIAGNOSTIC IMAGING; DROMEDARY; DRUG RESEARCH; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INCUBATION TIME; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; LABORATORY DIAGNOSIS; LABORATORY TEST; LACK OF DRUG EFFECT; LONG TERM CARE; MENTAL HEALTH; MIDDLE EAST RESPIRATORY SYNDROME; MORTALITY RATE; NONHUMAN; PATHOGENESIS; PATIENT CARE; PLASMA; PLASMA TRANSFUSION; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVOR; VIROLOGY; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 85082185623     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)33221-0     Document Type: Review

References (143)

1. WHO. SARS (severe acute respiratory syndrome). https://www.who.int/ith/diseases/sars/en/. (Accessed 12 February 2020)
2. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/. (Accessed 12 February 2020)
3. WHO. Coronavirus disease (COVID-19) outbreak. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (Accessed 23 February 2020)
4. WHO. A research and development blueprint for action to prevent epidemics. https://www.who.int/blueprint/en/. (Accessed 15 February 2020)
5. Peiris, JS, Yuen, KY, Osterhaus, AD, Stöhr, K, The severe acute respiratory syndrome. N Engl J Med 349 (2003), 2431–2441.
6. Zaki, AM, van Boheemen, S, Bestebroer, TM, Osterhaus, AD, Fouchier, RA, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
7. Hijawi, B, Abdallat, M, Sayaydeh, A, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 19 (2013), S12–S18.
8. Drosten, C, Kellam, P, Memish, ZA, Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 371 (2014), 1359–1360.
9. El-Kafrawy, SA, Corman, VM, Tolah, AM, et al. Enzootic patterns of Middle East respiratory syndrome coronavirus in imported African and local Arabian dromedary camels: a prospective genomic study. Lancet Planet Health 3 (2019), e521–e528.
10. Zumla, A, Hui, DS, Perlman, S, Middle East respiratory syndrome. Lancet 386 (2015), 995–1007.
11. Kim, KH, Tandi, TE, Choi, JW, Moon, JM, Kim, MS, Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect 95 (2017), 207–213.
12. Oh, MD, Park, WB, Park, SW, et al. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J Intern Med 33 (2018), 233–246.
13. Zhu, N, Zhang, D, Wang, W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020 published online January 24. DOI:10.1056/NEJMoa2001017.
14. Masters, PS, Perlman, S, Coronaviridae. Knipe, DM, Howley, PM, (eds.) Fields virology, 2013, Lippincott Williams & Wilkins, Philadelphia, PA, 825–858.
15. Raj, VS, Mou, H, Smits, SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
16. Walls, AC, Tortorici, MA, Bosch, BJ, et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531 (2016), 114–117.
17. Yuan, Y, Cao, D, Zhang, Y, et al. Cryo-em structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun, 8, 2017, 15092.
18. Fehr, AR, Perlman, S, Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282 (2015), 1–23.
19. WHO. Middle East respiratory syndrome coronavirus: case definition for reporting to WHO. https://www.who.int/csr/disease/coronavirus_infections/case_definition/en/. (Accessed 30 August 2017)
20. Conzade, R, Grant, R, Malik, MR, et al. Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases. Viruses, 10, 2018, 425.
21. Hui, DS, Azhar, EI, Kim, YJ, Memish, ZA, Oh, MD, Zumla, A, Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 18 (2018), e217–e227.
22. Kandeil, A, Gomaa, M, Nageh, A, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Africa and Middle East. Viruses, 11, 2019, 717.
23. Reusken, CB, Ababneh, M, Raj, VS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill, 18, 2013, 20662.
24. Azhar, EI, El-Kafrawy, SA, Farraj, SA, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 370 (2014), 2499–2505.
25. Haagmans, BL, Al Dhahiry, SH, Reusken, CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 14 (2014), 140–145.
26. Paden, CR, Yusof, M, Al Hammadi, ZM, et al. Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. Zoonoses Public Health 65 (2018), 322–333.
27. Adney, DR, van Doremalen, N, Brown, VR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 20 (2014), 1999–2005.
28. Khalafalla, AI, Lu, X, Al-Mubarak, AI, Dalab, AH, Al-Busadah, KA, Erdman, DD, MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013–2014. Emerg Infect Dis 21 (2015), 1153–1158.
29. Sikkema, RS, Farag, E, Islam, M, et al. Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review. Epidemiol Infect, 147, 2019, e84.
30. Sabir, JS, Lam, TT, Ahmed, MM, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351 (2016), 81–84.
31. FAO-OIE-WHO MERS Technical Working Group. MERS: progress on the global response, remaining challenges and the way forward. Antiviral Res 159 (2018), 35–44.
32. Kim, JI, Park, S, Bae, JY, Park, MS, Evolutionary relationship analysis of Middle East respiratory syndrome coronavirus 4a and 4b protein coding sequences. J Vet Sci, 20, 2019, e1.
33. Elkholy, AA, Grant, R, Assiri, A, Elhakim, M, Malik, MR, Van Kerkhove, MD, MERS-CoV infection among healthcare workers and risk factors for death: retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018. J Infect Public Health, 2019 published online May 2. DOI:10.1016/j.jiph.2019.04.011.
34. Al Hammadi, ZM, Chu, DK, Eltahir, YM, et al. Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015. Emerg Infect Dis 21 (2015), 2197–2200.
35. Alraddadi, BM, Al-Salmi, HS, Jacobs-Slifka, K, et al. Risk factors for Middle East respiratory syndrome coronavirus infection among healthcare personnel. Emerg Infect Dis 22 (2016), 1915–1920.
36. Farag, EA, Reusken, CB, Haagmans, BL, et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect Ecol Epidemiol, 5, 2015, 28305.
37. Kasem, S, Qasim, I, Al-Hufofi, A, et al. Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that have had contact with MERS patients in Saudi Arabia. J Infect Public Health 11 (2018), 331–338.
38. Muhairi, SA, Hosani, FA, Eltahir, YM, et al. Epidemiological investigation of Middle East respiratory syndrome coronavirus in dromedary camel farms linked with human infection in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 52 (2016), 848–854.
39. Zhou, J, Li, C, Zhao, G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv, 3, 2017, eaao4966.
40. Bernard-Stoecklin, S, Nikolay, B, Assiri, A, et al. Comparative analysis of eleven healthcare-associated outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) from 2015 to 2017. Sci Rep, 9, 2019, 7385.
41. Choi, S, Jung, E, Choi, BY, Hur, YJ, Ki, M, High reproduction number of Middle East respiratory syndrome coronavirus in nosocomial outbreaks: mathematical modelling in Saudi Arabia and South Korea. J Hosp Infect 99 (2018), 162–168.
42. Assiri, A, McGeer, A, Perl, TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369 (2013), 407–416.
43. Alanazi, KH, Killerby, ME, Biggs, HM, et al. Scope and extent of healthcare-associated Middle East respiratory syndrome coronavirus transmission during two contemporaneous outbreaks in Riyadh, Saudi Arabia, 2017. Infect Control Hosp Epidemiol 40 (2019), 79–88.
44. Amer, H, Alqahtani, AS, Alzoman, H, Aljerian, N, Memish, ZA, Unusual presentation of Middle East respiratory syndrome coronavirus leading to a large outbreak in Riyadh during 2017. Am J Infect Control 46 (2018), 1022–1025.
45. Kang, CK, Song, KH, Choe, PG, et al. Clinical and epidemiologic characteristics of spreaders of Middle East respiratory syndrome coronavirus during the 2015 outbreak in Korea. J Korean Med Sci 32 (2017), 744–749.
46. Alsaad, KO, Hajeer, AH, Al Balwi, M, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection—clinicopathological and ultrastructural study. Histopathology 72 (2018), 516–524.
47. Ng, DL, Al Hosani, F, Keating, MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 186 (2016), 652–658.
48. Yeung, ML, Yao, Y, Jia, L, et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat Microbiol, 1, 2016, 16004.
49. Corman, VM, Albarrak, AM, Omrani, AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 62 (2016), 477–483.
50. Widagdo, W, Sooksawasdi Na Ayudhya, S, Hundie, GB, et al. Host determinants of MERS-CoV transmission and pathogenesis. Viruses, 11, 2019, E280.
51. Leist, SR, Cockrell, AS, Genetically engineering a susceptible mouse model for MERS-CoV-induced acute respiratory distress syndrome. Methods Mol Biol 2099 (2020), 137–159.
52. Channappanavar, R, Perlman, S, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39 (2017), 529–539.
53. Cameron, MJ, Ran, L, Xu, L, et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81 (2007), 8692–8706.
54. Chu, H, Zhou, J, Wong, BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 454–455 (2014), 197–205.
55. Lau, SK, Lau, CC, Chan, KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 94 (2013), 2679–2690.
56. Zhou, J, Chu, H, Li, C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 209 (2014), 1331–1342.
57. Shin, HS, Kim, Y, Kim, G, et al. Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin Infect Dis 68 (2019), 984–992.
58. Drosten, C, Meyer, B, Müller, MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 371 (2014), 828–835.
59. Zhao, J, Alshukairi, AN, Baharoon, SA, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol, 2, 2017, eaan5393.
60. Alshukairi, AN, Khalid, I, Ahmed, WA, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis 22 (2016), 1113–1115.
61. Arabi, YM, Balkhy, HH, Hayden, FG, et al. Middle East respiratory syndrome. N Engl J Med 376 (2017), 584–594.
62. Cauchemez, S, Fraser, C, Van Kerkhove, MD, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 14 (2014), 50–56.
63. Breban, R, Riou, J, Fontanet, A, Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382 (2013), 694–699.
64. Kim, SH, Ko, JH, Park, GE, et al. Atypical presentations of MERS-CoV infection in immunocompromised hosts. J Infect Chemother 23 (2017), 769–773.
65. Drosten, C, Seilmaier, M, Corman, VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 13 (2013), 745–751.
66. Grant, R, Malik, MR, Elkholy, A, Van Kerkhove, MD, A review of asymptomatic and sub-clinical Middle East respiratory syndrome coronavirus infections. Epidemiol Rev, 2019 published online Nov 29. DOI:10.1093/epirev/mxz009.
67. WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr, 5, 2013.
68. Kim, JE, Heo, JH, Kim, HO, et al. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol 13 (2017), 227–233.
69. Alfaraj, SH, Al-Tawfiq, JA, Altuwaijri, TA, Alanazi, M, Alzahrani, N, Memish, ZA, Middle east respiratory syndrome coronavirus transmission among health care workers: implication for infection control. Am J Infect Control 46 (2018), 165–168.
70. Hui, DS, Memish, ZA, Zumla, A, Severe acute respiratory syndrome vs the Middle East respiratory syndrome. Curr Opin Pulm Med 20 (2014), 233–241.
71. Al-Tawfiq, JA, Kattan, RF, Memish, ZA, Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. World J Clin Pediatr 5 (2016), 391–396.
72. Alfaraj, SH, Al-Tawfiq, JA, Altuwaijri, TA, Memish, ZA, Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. Front Med 13 (2019), 126–130.
73. Memish, ZA, Al-Tawfiq, JA, Assiri, A, et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 33 (2014), 904–906.
74. Mobaraki, K, Ahmadzadeh, J, Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study. BMC Infect Dis, 19, 2019, 351.
75. Alfaraj, SH, Al-Tawfiq, JA, Memish, ZA, Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: report of two cases & review of the literature. J Microbiol Immunol Infect 52 (2019), 501–503.
76. WHO. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. https://www.who.int/csr/disease/coronavirus_infections/ipc-mers-cov/en/, 2015. (Accessed 26 September 2019)
77. WHO. Laboratory testing for middle east respiratory syndrome coronavirus. https://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1, 2018. (Accessed 3 October 2019)
78. CDC. CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.cdc.gov/coronavirus/mers/lab/lab-testing.html. (Accessed 21 February 2020)
79. Memish, ZA, Al-Tawfiq, JA, Makhdoom, HQ, et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 210 (2014), 1590–1594.
80. Oh, MD, Park, WB, Choe, PG, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med 375 (2016), 1303–1305.
81. Bermingham, A, Chand, MA, Brown, CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill, 17, 2012, 20290.
82. Alfaraj, SH, Al-Tawfiq, JA, Memish, ZA, Middle east respiratory syndrome coronavirus intermittent positive cases: implications for infection control. Am J Infect Control 47 (2019), 290–293.
83. WHO. Laboratory biorisk management for laboratories handling human specimens suspected of confirmed to contain novel coronavirus: interim recommendations. https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus_19Feb13.pdf?ua=1, 2013. (Accessed 3 October 2019)
84. Kelly-Cirino, C, Mazzola, LT, Chua, A, Oxenford, CJ, Van Kerkhove, MD, An updated roadmap for MERS-CoV research and product development: focus on diagnostics. BMJ Glob Health, 4, 2019, e001105.
85. Frans, G, Beuselinck, K, Peeters, B, et al. Migrating a lab-developed MERS-CoV real-time PCR to 3 “sample to result” systems: experiences on optimization and validation. Diagn Microbiol Infect Dis 94 (2019), 349–354.
86. Huang, P, Wang, H, Cao, Z, et al. A rapid and specific assay for the detection of MERS-CoV. Front Microbiol, 9, 2018, 1101.
87. Hashem, AM, Al-Amri, SS, Al-Subhi, TL, et al. Development and validation of different indirect ELISAS for MERS-CoV serological testing. J Immunol Methods 466 (2019), 41–46.
88. Park, SW, Perera, RA, Choe, PG, et al. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection. Euro Surveill 20 (2015), 1–5.
89. Perera, RA, Wang, P, Gomaa, MR, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in Dromedary camels in Egypt, June 2013. Euro Surveill, 18, 2013, 20574.
90. Okba, NMA, Raj, VS, Widjaja, I, et al. Sensitive and specific detection of low-level antibody responses in mild Middle East respiratory syndrome coronavirus infections. Emerg Infect Dis 25 (2019), 1868–1877.
91. Das, KM, Lee, EY, Al Jawder, SE, et al. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients. AJR Am J Roentgenol 205 (2015), W267–W274.
92. Das, KM, Lee, EY, Langer, RD, Larsson, SG, Middle East respiratory syndrome coronavirus: what does a radiologist need to know?. AJR Am J Roentgenol 206 (2016), 1193–1201.
93. Ajlan, AM, Ahyad, RA, Jamjoom, LG, Alharthy, A, Madani, TA, Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am J Roentgenol 203 (2014), 782–787.
94. Das, KM, Lee, EY, Enani, MA, et al. CT correlation with outcomes in 15 patients with acute Middle East respiratory syndrome coronavirus. AJR Am J Roentgenol 204 (2015), 736–742.
95. Das, KM, Lee, EY, Singh, R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 27 (2017), 342–349.
96. WHO. Home care for patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection presenting with mild symptoms and management of contacts interim guidance. https://apps.who.int/iris/bitstream/handle/10665/272948/WHO-MERS-IPC-18.1-eng.pdf?ua=1, June 2018. (Accessed 24 February 2020)
97. Momattin, H, Al-Ali, AY, Al-Tawfiq, JA, A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-CoV). Travel Med Infect Dis 30 (2019), 9–18.
98. Arabi, Y, Balkhy, H, Hajeer, AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus, 4, 2015, 709.
99. Arabi, YM, Alothman, A, Balkhy, HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 19, 2018, 81.
100. Arabi, YM, Mandourah, Y, Al-Hameed, F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197 (2018), 757–767.
101. Behzadi, MA, Leyva-Grado, VH, Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and Middle East respiratory syndrome coronavirus infections. Front Microbiol, 10, 2019, 1327.
102. Beigel, JH, Nam, HH, Adams, PL, et al. Advances in respiratory virus therapeutics—a meeting report from the 6th ISIRV antiviral group conference. Antiviral Res 167 (2019), 45–67.
103. Rabaan, AA, Alahmed, SH, Bazzi, AM, Alhani, HM, A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol 66 (2017), 1261–1274.
104. Zhou, Y, Yang, Y, Huang, J, Jiang, S, Du, L, Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses, 11, 2019, 60.
105. Zumla, A, Chan, JF, Azhar, EI, Hui, DS, Yuen, KY, Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15 (2016), 327–347.
106. Zhao, J, Perera, RA, Kayali, G, Meyerholz, D, Perlman, S, Peiris, M, Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol 89 (2015), 6117–6120.
107. Ko, JH, Seok, H, Cho, SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 23 (2018), 617–622.
108. Arabi, YM, Deeb, AM, Al-Hameed, F, et al. Macrolides in critically ill patients with Middle East respiratory syndrome. Int J Infect Dis 81 (2019), 184–190.
109. Alraddadi, BM, Qushmaq, I, Al-Hameed, FM, et al. Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza Other Respir Viruses 13 (2019), 382–390.
110. Stalin Raj, V, Okba, NMA, Gutierrez-Alvarez, J, et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Sci Adv, 4, 2018, eaas9667.
111. Wang, L, Shi, W, Chappell, JD, et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. J Virol 92 (2018), e02002–e02017.
112. Widjaja, I, Wang, C, van Haperen, R, et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect 8 (2019), 516–530.
113. Lee, SM, Kang, WS, Cho, AR, Kim, T, Park, JK, Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. Compr Psychiatry 87 (2018), 123–127.
114. Ahmed, AE, The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis, 17, 2017, 615.
115. Park, JE, Jung, S, Kim, A, Park, JE, MERS transmission and risk factors: a systematic review. BMC Public Health, 18, 2018, 574.
116. Rahman, A, Sarkar, A, Risk factors for fatal Middle East respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO line list, 2013–2018. Am J Public Health 109 (2019), 1288–1293.
117. Sha, J, Li, Y, Chen, X, et al. Fatality risks for nosocomial outbreaks of Middle East respiratory syndrome coronavirus in the Middle East and South Korea. Arch Virol 162 (2017), 33–44.
118. Seys, LJM, Widagdo, W, Verhamme, FM, et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clin Infect Dis 66 (2018), 45–53.
119. Batawi, S, Tarazan, N, Al-Raddadi, R, et al. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes, 17, 2019, 101.
120. Ngai, JC, Ko, FW, Ng, SS, To, KW, Tong, M, Hui, DS, The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 15 (2010), 543–550.
121. WHO. WHO target product profiles for MERS-CoV vaccines. https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1&ua=1, 2017. (Accessed 30 August 2019)
122. Schindewolf, C, Menachery, VD, Middle East respiratory syndrome vaccine candidates: cautious optimism. Viruses, 11, 2019, e74.
123. Hemida, MG, Middle East respiratory syndrome coronavirus and the One Health concept. PeerJ, 7, 2019, e7556.
124. Hemida, MG, Alnaeem, A, Some one health based control strategies for the Middle East respiratory syndrome coronavirus. One Health, 8, 2019, 100102.
125. Park, S, Park, JY, Song, Y, How, SH, Jung, KS, Emerging respiratory infections threatening public health in the Asia-Pacific region: a position paper of the Asian Pacific society of respirology. Respirology 24 (2019), 590–597.
126. Zumla, A, Dar, O, Kock, R, et al. Taking forward a ‘one health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. Int J Infect Dis 47 (2016), 5–9.
127. Kirchdoerfer, RN, Ward, AB, Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun, 10, 2019, 2342.
128. Chu, DKW, Hui, KPY, Perera, R, et al. MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity. Proc Natl Acad Sci USA 115 (2018), 3144–3149.
129. Lamers, MM, Raj, VS, Shafei, M, et al. Deletion variants of Middle East respiratory syndrome coronavirus from humans, Jordan, 2015. Emerg Infect Dis 22 (2016), 716–719.
130. Xie, Q, Cao, Y, Su, J, et al. Two deletion variants of Middle East respiratory syndrome coronavirus found in a patient with characteristic symptoms. Arch Virol 162 (2017), 2445–2449.
131. Knoops, K, Kikkert, M, Worm, SH, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol, 6, 2008, e226.
132. Amer, H, Alqahtani, AS, Alaklobi, F, Altayeb, J, Memish, ZA, Healthcare worker exposure to Middle East respiratory syndrome coronavirus (MERS-CoV): revision of screening strategies urgently needed. Int J Infect Dis 71 (2018), 113–116.
133. Al-Abdallat, MM, Payne, DC, Alqasrawi, S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 59 (2014), 1225–1233.
134. Alenazi, TH, Al Arbash, H, El-Saed, A, et al. Identified transmission dynamics of Middle East respiratory syndrome coronavirus infection during an outbreak: implications of an overcrowded emergency department. Clin Infect Dis 65 (2017), 675–679.
135. Hui, DS, Peiris, M, Middle East respiratory syndrome. Am J Respir Crit Care Med 192 (2015), 278–279.
136. Nam, HS, Park, JW, Ki, M, Yeon, MY, Kim, J, Kim, SW, High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Int J Infect Dis 58 (2017), 37–42.
137. Oboho, IK, Tomczyk, SM, Al-Asmari, AM, et al. 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. N Engl J Med 372 (2015), 846–854.
138. Hunter, JC, Nguyen, D, Aden, B, et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis 22 (2016), 647–656.
139. Jo, S, Kim, H, Kim, S, Shin, DH, Kim, MS, Characteristics of flavonoids as potent MERS-CoV 3c-like protease inhibitors. Chem Biol Drug Des 94 (2019), 2023–2030.
140. Mustafa, S, Balkhy, H, Gabere, MN, Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review. J Infect Public Health 11 (2018), 9–17.
141. 4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 93 (2019), e01348–e01419.
142. Sheahan, TP, Sims, AC, Graham, RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 9, 2017, eaal3653.
143. Taylor, R, Kotian, P, Warren, T, et al. BCX4430—a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health 9 (2016), 220–226.